摘要 |
Tezacitabine, either alone or in combination with one or more nucleoside analogs or prodrugs thereof, can be use to treat nucleoside analog-resistant tumor, particularly gemcitabine-resistant tumors. Screening tumor samples for ras mutations or screening tumor or other patient samples for levels of cytidine deaminase activity or expression, for levels of thymidine phosphorylase activity, or for levels of thymidylate synthase activity or expression are useful for assessing whether a tumor of a patient is likely to respond to treatment with various nucleoside analogs, particularly tezacitabine, gemcitabine, and combinations of nucleoside analogs or prodrugs thereof. |
申请人 |
CHIRON CORPORATION;AUKERMANN, SHARON, LEA;BRONSON, MICHELLE, D.;FANTL, WENDY;HIBNER, BARBARA |
发明人 |
AUKERMANN, SHARON, LEA;BRONSON, MICHELLE, D.;FANTL, WENDY;HIBNER, BARBARA |